1-11 of 11
Lyudmila Bazhenova
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Edwin Roger Parra, Jiexin Zhang, Dzifa Yawa Duose, Edgar Gonzalez-Kozlova, Mary W. Redman, Hong Chen, Ganiraju C. Manyam, Gayatri Kumar, Jianhua Zhang, Xingzhi Song, Rossana Lazcano, Mario L. Marques-Piubelli, Caddie Laberiano-Fernandez, Frank Rojas, Baili Zhang, Len Taing, Aashna Jhaveri, Jacob Geisberg, Jennifer Altreuter, Franziska Michor, James Provencher, Joyce Yu, Ethan Cerami, Radim Moravec, Kasthuri Kannan, Rajyalakshmi Luthra, Gheath Alatrash, Hsin-Hui Huang, Hui Xie, Manishkumar Patel, Kai Nie, Jocelyn Harris, Kimberly Argueta, James Lindsay, Roshni Biswas, Stephen Van Nostrand, Seunghee Kim-Schulze, Jhanelle E. Gray, Roy S. Herbst, Ignacio I. Wistuba, Scott Gettinger, Karen Kelly, Lyudmila Bazhenova, Sacha Gnjatic, J. Jack Lee, Jianjun Zhang, Cara Haymaker
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1655–1668.
https://doi.org/10.1158/1078-0432.CCR-23-0251
Published: 15 April 2024
View article titled, Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
Open the PDF for Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial in another window
Includes: Supplementary data
Journal Articles

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors

George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2196.
https://doi.org/10.1158/1078-0432.CCR-22-1108
Published: 13 May 2022
View article titled, Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with <em>NTRK</em> Fusion–Positive Solid Tumors
Open the PDF for Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with <em>NTRK</em> Fusion–Positive Solid Tumors in another window
Journal Articles

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1302–1312.
https://doi.org/10.1158/1078-0432.CCR-21-3597
Published: 01 April 2022
View article titled, Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <em>NTRK</em> Fusion-Positive Solid Tumors
Open the PDF for Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <em>NTRK</em> Fusion-Positive Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

Edward B. Garon, Alexander I. Spira, Melissa Johnson, Lyudmila Bazhenova, Joseph Leach, Amy L. Cummings, Albert Candia, Robert L. Coffman, Mary J. Janatpour, Robert Janssen, Erick Gamelin, Laura Q.M. Chow
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4566–4573.
https://doi.org/10.1158/1078-0432.CCR-21-0263
Published: 15 August 2021
View article titled, A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer
Open the PDF for A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Vivek Subbiah, Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho, Herbert H. Loong, Caroline E. McCoach, Jared Weiss, Yu Jung Kim, Lyudmila Bazhenova, Keunchil Park, Haruko Daga, Benjamin Besse, Oliver Gautschi, Christian Rolfo, Edward Y. Zhu, Jennifer F. Kherani, Xin Huang, Suhyun Kang, Alexander Drilon
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4160–4167.
https://doi.org/10.1158/1078-0432.CCR-21-0800
Published: 01 August 2021
View article titled, Intracranial Efficacy of Selpercatinib in <em>RET</em> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
Open the PDF for Intracranial Efficacy of Selpercatinib in <em>RET</em> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial in another window
Includes: Supplementary data
Journal Articles

Abstract 09: Cancers with NTRK gene fusions: Molecular characteristics and prognosis

Lyudmila Bazhenova, Xiaolong Jiao, Andrew Lokker, Jeremy Snider, Emily Castellanos, Shivani Nanda, Virginia Fisher, Jihong Zong, Karen Keating, Marc Fellous
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_1): 09.
https://doi.org/10.1158/1557-3265.ADVPRECMED20-09
Published: 15 June 2020
View article titled, Abstract 09: Cancers with <em>NTRK</em> gene fusions: Molecular characteristics and prognosis
Journal Articles

Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

Julia K. Rotow, Philippe Gui, Wei Wu, Victoria M. Raymond, Richard B. Lanman, Frederic J. Kaye, Nir Peled, Ferran Fece de la Cruz, Brandon Nadres, Ryan B. Corcoran, Iwei Yeh, Boris C. Bastian, Petr Starostik, Kimberly Newsom, Victor R. Olivas, Alexander M. Wolff, James S. Fraser, Eric A. Collisson, Caroline E. McCoach, D. Ross Camidge, Jose Pacheco, Lyudmila Bazhenova, Tianhong Li, Trever G. Bivona, Collin M. Blakely
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (2): 439–449.
https://doi.org/10.1158/1078-0432.CCR-19-1667
Published: 15 January 2020
View article titled, Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
Open the PDF for Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer in another window
Includes: Supplementary data
Journal Articles

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation

Benjamin P. Brown, Yun-Kai Zhang, David Westover, Yingjun Yan, Huan Qiao, Vincent Huang, Zhenfang Du, Jarrod A. Smith, Jeffrey S. Ross, Vincent A. Miller, Siraj Ali, Lyudmila Bazhenova, Alexa B. Schrock, Jens Meiler, Christine M. Lovly
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (11): 3341–3351.
https://doi.org/10.1158/1078-0432.CCR-18-3829
Published: 03 June 2019
View article titled, On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation
Open the PDF for On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation in another window
Includes: Multimedia, Supplementary data
Journal Articles

Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma

Maria C. Schwaederlé, Sandip P. Patel, Hatim Husain, Megumi Ikeda, Richard B. Lanman, Kimberly C. Banks, AmirAli Talasaz, Lyudmila Bazhenova, Razelle Kurzrock
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (17): 5101–5111.
https://doi.org/10.1158/1078-0432.CCR-16-2497
Published: 31 August 2017
View article titled, Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma
Open the PDF for Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma

Raffit Hassan, Hedy L. Kindler, Thierry Jahan, Lyudmila Bazhenova, Martin Reck, Anish Thomas, Ira Pastan, Jeff Parno, Daniel J. O'Shannessy, Penny Fatato, Julia D. Maltzman, Bruce A. Wallin
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 5927–5936.
https://doi.org/10.1158/1078-0432.CCR-14-0804
Published: 30 November 2014
View article titled, Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
Open the PDF for Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Eric B. Haura, Alejandro D. Ricart, Timothy G. Larson, Philip J. Stella, Lyudmila Bazhenova, Vincent A. Miller, Roger B. Cohen, Peter D. Eisenberg, Paulina Selaru, Keith D. Wilner, Shirish M. Gadgeel
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (8): 2450–2457.
https://doi.org/10.1158/1078-0432.CCR-09-1920
Published: 14 April 2010
View article titled, A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer in another window